Source - LSE Regulatory
RNS Number : 2682X
Nuformix PLC
25 August 2022
 

Nuformix plc

 

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,  announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting.  The results of the proxy voting position received in advance of the meeting are reported below:

 

 

Resolution

Ordinary/ Special

For

 

Against

 

Total votes cast




No. of votes

%

No. of votes

%


1

To receive the annual report and accounts for the year ended 31 March 2022

 

Ordinary

150,018,268

100

0

0

150,018,268

2

To approve the Remuneration Policy

 

Ordinary

149,469,749

99.86

217,007

0.14

149,686,756

3

To re-appoint Julian Gilbert as a director

 

Ordinary

150,096,308

99.93

106,121

0.07

150,202,429

4

To re-appoint s Madeleine Kennedy as a director

 

Ordinary

150,096,308

99.93

106,121

0.07

150,202,429

5

To re-appoint Jeffreys Henry Audit Limited as auditor

 

Ordinary

150,096,308

99.93

106,121

0.07

150,202,429

6

To authorise the Directors to determine the auditor's fees.

 

Ordinary

149,295,087

99.40

907,342

0.60

150,202,429

7

To authorise the Directors to allot shares.

 

Ordinary

146,859,280

97.78

3,331,149

2.22

150,190,429

8

To authorise the Directors to disapply pre-emption rights.

 

Special

146,905,107

97.81

3,285,322

2.19

150,190,429

9

To authorise the Company to purchase its own shares.

 

Special

150,139,861

99.93

112,568

0.07

150,252,429

10

To authorise calling of a general meeting on 14 clear days' notice.

 

Special

150,102,429

99.93

100,000

0.07

150,202,429

 

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 709,309,368 ordinary shares of £0.001 each.

Enquiries:

  

Nuformix plc


Dr Daniel Gooding, Executive Director

Dr Julian Gilbert, Non-executive Chairman

 

Via IFC Advisory

 

Stanford Capital Partners Limited


Tom Price / Patrick Claridge (Corporate Finance)

+44 (0) 20 3650 3650

John Howes (Corporate Broking)

+44 (0) 20 3650 3652

 

IFC Advisory Limited


Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630

nuformix@investor-focus.co.uk

               

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

 

For more information, please visit www.nuformix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGXELFLLVLXBBV
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Nuformix PLC (NFX)

+0.00p (+1.22%)
delayed 07:00AM